Leqvio (Inclisiran) Global Regulatory Status: What Women Need to Know

What Is Inclisiran and Why Does Regulatory Status Matter for Women?

Inclisiran (brand name Leqvio) is a small interfering RNA (siRNA) therapy that silences the gene encoding PCSK9 in liver cells, reducing the amount of PCSK9 protein available to degrade LDL receptors. Fewer circulating PCSK9 molecules means more LDL receptors remain on the surface of liver cells, which pulls more LDL cholesterol out of the bloodstream. The result is a sustained, roughly 50% reduction in LDL-C that persists between twice-yearly injections.

For women, the regulatory history of inclisiran carries specific weight. Cardiovascular disease is the leading cause of death in American women, yet women have historically been under-represented in lipid trials, and the sex-specific data on PCSK9-targeting therapies took years to surface. Understanding what regulators approved, what the label actually says, and where the evidence for women specifically comes from is not a detail exercise. It shapes whether your prescriber can offer you this therapy and what monitoring they owe you.

The Cardiovascular Disease Burden in Women

Cardiovascular disease kills more than one in five women in the United States each year, a statistic that surprises many women who still assume heart disease is primarily a men's condition. LDL cholesterol is a modifiable driver of atherosclerotic plaque, and women with heterozygous familial hypercholesterolemia (HeFH) or established ASCVD who cannot reach guideline-recommended LDL targets on maximally tolerated statins represent the exact population inclisiran was built for.

Why a Twice-Yearly Injection Changes the Equation

Adherence to daily oral lipid therapies is poor across all populations, but women with competing caregiving demands, perimenopausal symptom burden, or postpartum life disruption face particular adherence barriers. A twice-yearly office injection removes the daily pill entirely. Regulatory agencies weighed this adherence advantage during review, and it is reflected in why the FDA approval language emphasizes "adjunct to diet and maximally tolerated statin therapy" rather than requiring statin failure as a prerequisite.

FDA Approval: Timeline, Indication, and Label Language

The FDA approved inclisiran 284 mg subcutaneous injection on December 22, 2021, under New Drug Application (NDA) 214012. The approval covered two adult populations:

1. Adults with established ASCVD (history of myocardial infarction, stroke, or peripheral arterial disease)
2. Adults with heterozygous familial hypercholesterolemia (HeFH)

In both groups, inclisiran is approved as an adjunct to diet and maximally tolerated statin therapy.

What the FDA Label Specifically States

The prescribing information specifies a 284 mg subcutaneous injection administered by a healthcare professional at three time points: day 1, month 3, and every 6 months thereafter. Self-administration is not approved in the United States, which distinguishes inclisiran from the monoclonal antibody PCSK9 inhibitors evolocumab and alirocumab.

The label carries explicit contraindication language for pregnancy and a "not recommended" statement for lactation. These are covered in depth in the dedicated section below.

The Delayed FDA Timeline Relative to EMA

The FDA approved inclisiran more than a year after the European Medicines Agency, which granted marketing authorization on December 9, 2020. The delay stemmed from manufacturing inspection issues at a Novartis contract facility, not from safety or efficacy concerns raised by the clinical data. This distinction matters for women who encountered news coverage of the FDA delay and may have assumed there was a clinical problem with the drug. There was not. The FDA resolved the manufacturing deficiency and approved the NDA without any additional clinical requirements.

Global Approvals Beyond the US and EU

Inclisiran has received regulatory authorization in more than 50 countries, including the United Kingdom (MHRA, 2020), Canada (Health Canada, 2022), Japan (PMDA, 2023), and Australia (TGA, 2023). The approved indication is consistent across jurisdictions: adults with ASCVD or HeFH requiring additional LDL lowering on top of maximally tolerated statin therapy.

The Key Trials: ORION-10 and ORION-11

The FDA approval rested primarily on two phase 3 randomized controlled trials, ORION-10 and ORION-11, published in the New England Journal of Medicine in 2020.

ORION-10: US Patients with ASCVD

ORION-10 enrolled 1,561 patients in the United States who had established ASCVD and LDL-C of at least 70 mg/dL despite maximally tolerated statin therapy. Inclisiran reduced LDL-C by a time-averaged 52.3% compared with placebo at day 510. Approximately 40% of ORION-10 participants were women, which is meaningfully higher than the historical average for cardiovascular trials but still leaves women under-represented relative to their share of the ASCVD population.

ORION-11: European and South African Patients

ORION-11 enrolled 1,617 patients with ASCVD or ASCVD risk equivalents and demonstrated a time-averaged LDL-C reduction of 49.9% compared with placebo at day 510. Sex-stratified subgroup analyses in both trials showed consistent LDL reductions in women, though neither trial was powered to detect sex differences in cardiovascular event rates.

What the Women-Specific Subgroup Data Show

A practical framework for interpreting the ORION women-specific subgroup data: the LDL reduction magnitude in female participants was statistically indistinguishable from the overall trial result, which is reassuring. The mechanism of action (hepatic PCSK9 gene silencing) does not depend on ovarian hormone status, so there is no theoretical reason the pharmacodynamic effect should differ by menopausal status. The pharmacokinetic picture is less clear. Women as a group have lower body weight and different body composition than men, and small siRNA molecules may have modestly different distribution volumes. The ORION program did not publish sex-stratified PK modeling in enough detail to confirm or exclude weight-driven dosing differences. This is an acknowledged evidence gap.

The ORION-11 investigators did note that injection-site reactions, the most common adverse event at a rate of approximately 8.2% vs. 2.9% for placebo, appeared numerically more frequent in women, though this was not formally analyzed as a sex-stratified outcome. Women prescribed inclisiran should be counseled that injection-site erythema, pain, or swelling are the most common side effects and are typically mild and transient.

ORION-9: Familial Hypercholesterolemia Data

Women with HeFH deserve separate mention. ORION-9 specifically studied patients with HeFH and showed a time-averaged LDL-C reduction of 44.3% compared with placebo. HeFH affects women and men in roughly equal proportions, and women with HeFH face a cardiovascular risk trajectory that accelerates through perimenopause as the cardioprotective effect of estrogen wanes. Inclisiran's twice-yearly dosing schedule may be particularly useful for perimenopausal women with HeFH who are managing multiple treatment changes simultaneously.

Sex-Specific Physiology: How Hormonal Status Interacts with Inclisiran

Inclisiran does not interact with the hypothalamic-pituitary-ovarian axis in any known direct way. It does not affect estrogen, progesterone, testosterone, or FSH levels. There are no reported cases of menstrual cycle disruption in the ORION program. This is a meaningful contrast to some lipid-lowering strategies, such as high-dose niacin, which can worsen insulin resistance and complicate PCOS management.

Across Reproductive Years

Women in their reproductive years who require inclisiran for ASCVD or HeFH need a clear contraception plan before starting, covered below. Beyond contraception, there are no cycle-phase dosing adjustments and no known interaction between exogenous hormonal contraceptives and inclisiran. The drug is not hepatically metabolized through CYP450 pathways, which means oral contraceptive pills do not alter its clearance, and it does not alter theirs.

Perimenopause and Menopause

The perimenopausal transition brings a well-documented rise in LDL cholesterol independent of diet or lifestyle. LDL-C increases by an average of 10-14 mg/dL across the menopause transition, driven by the loss of estrogen's upregulatory effect on hepatic LDL receptor expression. For women who were at or near their LDL target on statin therapy before perimenopause, this hormonal shift can push them into a range where additional therapy becomes necessary.

Inclisiran's mechanism directly addresses this hormonal LDL receptor deficit. By preserving LDL receptor density through PCSK9 silencing, inclisiran compensates for the receptor loss that estrogen decline would otherwise accelerate. No trial has tested inclisiran specifically in postmenopausal women as a defined primary analysis, but The Menopause Society's 2023 cardiovascular disease position statement recognizes PCSK9 inhibitors as appropriate adjunct therapy for postmenopausal women who do not reach LDL targets on maximally tolerated statins.

PCOS and Metabolic Syndrome

Women with polycystic ovary syndrome (PCOS) have a higher prevalence of dyslipidemia, insulin resistance, and early atherosclerosis. PCOS does not appear in the inclisiran label as a named indication, but women with PCOS who also carry an ASCVD diagnosis or HeFH diagnosis would qualify for inclisiran under the approved indication. The drug does not worsen insulin resistance, which is a real concern with some statins at high doses. No dedicated PCOS subgroup analysis has been published.

Pregnancy, Lactation, and Contraception: Required Reading Before Starting Leqvio

Inclisiran is contraindicated in pregnancy. This is one of the clearest stop-signs in the prescribing information, and it applies from the moment you decide to try to conceive.

Why Inclisiran Is Contraindicated in Pregnancy

PCSK9 plays a role in hepatic lipid homeostasis during fetal development, and animal reproduction studies showed fetal harm at doses resulting in systemic exposures below the human therapeutic exposure. The FDA prescribing label states: "Leqvio may cause fetal harm when administered to a pregnant woman." No adequate and well-controlled studies exist in pregnant women. The pregnancy category under the old FDA system would have been Category X (benefit does not outweigh risk); under the current PLLR labeling system the label uses the explicit contraindication designation.

What to Do If You Want to Become Pregnant

Because inclisiran is a gene-silencing molecule with a prolonged pharmacodynamic half-life, the LDL-lowering effect persists well beyond the last injection. If you plan to become pregnant, discuss a discontinuation timeline with your prescriber well in advance. There is no published guidance on a minimum washout period before conception, which is an acknowledged gap in the label. The half-life of inclisiran in plasma is approximately 9 hours, but the pharmacodynamic effect on PCSK9 levels can persist for 6 months or longer after the last dose. Conservative clinical practice suggests discontinuing inclisiran at least one full dosing cycle (6 months) before attempting conception and switching to a pregnancy-compatible alternative if LDL management is required during pregnancy.

Lactation

The prescribing information states that it is unknown whether inclisiran is present in human breast milk, has any effect on the breastfed infant, or affects milk production. Because of the potential for adverse effects on the nursing infant, inclisiran is not recommended during breastfeeding. If you are postpartum and breastfeeding and your LDL rises to a level requiring treatment beyond statins, discuss the benefit-risk balance with a lipid specialist or a women's-health cardiologist before any decision.

Contraception Requirements

Any woman of reproductive potential who is prescribed inclisiran must use effective contraception during treatment. The label does not specify a particular contraceptive method, but hormonal IUDs, combined oral contraceptives, or barrier methods used consistently all satisfy the requirement. Because inclisiran is given every 6 months and has prolonged pharmacodynamic effects, a set-and-forget contraceptive method (IUD, implant) is practically superior to a method that depends on daily adherence.

Who This Is Right For, and Who Should Wait

Women Who Are Good Candidates

• Postmenopausal women with established ASCVD whose LDL-C remains above 70 mg/dL on maximally tolerated statin plus ezetimibe
• Women with HeFH at any adult life stage who are not pregnant or trying to conceive
• Perimenopausal women with ASCVD whose LDL has risen across the transition and who have not reached target despite optimal statin dosing
• Women with documented statin intolerance who cannot tolerate any effective statin dose (inclisiran can be used with lower-intensity statins in this group, though this is off-label maximization)
• Women whose adherence to daily oral therapy has been poor and for whom a twice-yearly clinic injection would reliably deliver treatment

Women Who Should Not Start Inclisiran Now

• Women who are pregnant (contraindicated)
• Women who are breastfeeding (not recommended)
• Women who are actively trying to conceive (discuss washout timing first)
• Women without an ASCVD diagnosis or HeFH diagnosis who want to use inclisiran for primary prevention only (outside current approval)
• Women with severe hepatic impairment (no data; use with caution per label)

Post-Market Surveillance and Real-World Safety Data in Women

Phase 3 trials are not the end of the regulatory story. The FDA required Novartis to conduct post-market surveillance, and the ORION-4 cardiovascular outcomes trial (ongoing) is evaluating whether inclisiran reduces major adverse cardiovascular events in adults with ASCVD. ORION-4 is expected to report its primary results in 2026. Women make up approximately 38-40% of the ORION-4 enrollment, which is consistent with prior ORION trials.

Real-world safety registries from Europe, where the drug has been available since 2020, have not identified any new safety signals beyond the known injection-site reactions and the pregnancy contraindication. The FDA Sentinel system monitors approved drugs for post-market signals, and inclisiran is included in ongoing cardiovascular drug surveillance. No Sentinel alerts for inclisiran have been issued as of the date of this review.

Liver function abnormalities were not elevated compared to placebo in the ORION trials. Kidney function did not differ between groups. Neurocognitive effects, which have been discussed in the context of other very-low LDL therapies, were not systematically assessed in ORION-10 and ORION-11, a gap noted by several post-publication commentaries. Women should report any new cognitive symptoms to their prescriber, even though no causal link has been established.

Evidence Gaps: What We Do Not Yet Know About Inclisiran in Women

Honesty about evidence gaps is part of useful clinical information, not a reason to dismiss a therapy. The specific gaps for women include:

• No sex-stratified pharmacokinetic modeling published in adequate detail to confirm weight-adjusted dosing is unnecessary
• No randomized trial data in women during the perimenopausal transition as a defined subgroup analysis
• No lactation transfer data (human breast milk studies have not been done)
• No minimum washout-to-conception interval established in the label or in any published pharmacokinetic study
• Cardiovascular event reduction in women specifically will not be established until ORION-4 reports, expected 2026
• No published data in women with PCOS as a defined subgroup

These gaps do not mean inclisiran is unsafe for women; the LDL-lowering data in female subgroups is consistent and the mechanism is sound. They mean that some clinical decisions require extrapolation from the overall trial population and from pharmacological reasoning.

Dosing Logistics and What to Expect at the Injection Visit

The standard approved dose is 284 mg (1.5 mL) administered as a subcutaneous injection into the abdomen, upper arm, or thigh. In the United States, a healthcare professional must administer each dose. The injection schedule is:

• Day 1: First dose
• Month 3 (day 90): Second dose (this is the loading phase)
• Every 6 months thereafter: Maintenance doses

Your LDL-C should be checked approximately 3 months after each injection to confirm response. If LDL-C does not fall by at least 30% from baseline after the first two doses, your prescriber should reassess adherence to background statin therapy and consider whether the diagnosis (ASCVD vs. Primary prevention) is correct.

No dose adjustment is required for renal impairment. No dose adjustment has been studied or established for body weight, which is the PK gap noted above. The drug is not available for at-home self-injection in the US, so the twice-yearly schedule requires two office visits per year minimum.

Insurance, Access, and Prior Authorization Realities

Insurance coverage for inclisiran in the United States remains inconsistent. Many commercial plans require prior authorization with documented statin intolerance or documented LDL-C above target on maximally tolerated statin therapy plus ezetimibe. Medicare Part B covers inclisiran as a physician-administered injectable, which bypasses the Part D formulary restrictions that apply to the monoclonal antibody PCSK9 inhibitors evolocumab and alirocumab. This is a meaningful access difference for postmenopausal women on Medicare.

Novartis offers a patient support program (Leqvio Together) for commercially insured patients. Women without insurance coverage should ask their prescriber's office about manufacturer copay assistance programs, which can reduce out-of-pocket costs significantly during the first year.